Endocrinology, Vol 124, 798-804, Copyright © 1989 by Endocrine Society

ARTICLES

The gonadotropin-releasing hormone pituitary receptor interacts with a guanosine triphosphate-binding protein: differential effects of guanyl nucleotides on agonist and antagonist binding

MH Perrin, Y Haas, J Porter, J Rivier and W Vale
Clayton Foundation Laboratories for Peptide Biology, Salk Institute, La Jolla, California 92037.

Binding of the GnRH agonist [DAla6,NMe-Leu7,Pro9Net]GnRH to bovine anterior pituitary membranes is inhibited by guanyl nucleotides. The effect of guanyl nucleotides is temperature dependent, in that significant binding inhibition is observed when the receptor-hormone interaction is measured at 37 C, and no inhibition is seen at 4 C. Micromolar concentrations of the nonhydrolyzable GTP analog 5'- guanylylimidodiphosphate [Gpp(NH)p] displace the bound agonist in a dose-dependent manner, with half-maximal displacement occurring in a concentration range of 0.1-0.5 microM, and maximum displacement occurring at a concentration of 50 microM Gpp(NH)p. At a concentration of 50 microM, the other nucleotides GTP and GDP inhibit binding to a lesser extent, while GMP, cGMP, 5'-adenylylimidodiphosphate [App(NH)p], ATP, and cAMP have no effect on the binding. At 37 C, Gpp(NH)p reduces the affinity of the agonist by a factor of 6 and increases its dissociation rate. In the presence of Gpp(NH)p at 37 C, there is also a 2-fold increase in the total number of binding sites. Under the same conditions as those used for the agonist, there is no displacement of the bound antagonist [Ac-D2Nal1,4ClDPhe2,D3Pal3,DLys6,Lys8,D Ala10]- GnRH by doses up to 50 microM Gpp(NH)p. The modulation of the binding of the agonist, but not that of the antagonist, by guanyl nucleotides is characteristic of receptors that are coupled to GTP-binding proteins. Thus, the GnRH receptor appears to be coupled to a GTP- binding protein that may play a role in the mechanism of action of GnRH at the pituitary.

This article has been cited by other articles:

				S. Kitanovic, T. Yuen, C. A. Flanagan, B. J. Ebersole, and S. C. Sealfon Insertional Mutagenesis of the Arginine Cage Domain of the Gonadotropin-Releasing Hormone Receptor Mol. Endocrinol., March 1, 2001; 15(3): 390 - 397. [Abstract] [Full Text]

				J. D. Jacobson, M. A. Ansari, M. Kinealy, and V. Muthukrishnan Gender-Specific Exacerbation of Murine Lupus by Gonadotropin-Releasing Hormone: Potential Role of G{alpha}q/11 Endocrinology, August 1, 1999; 140(8): 3429 - 3437. [Abstract] [Full Text]

				M. H. Perrin, S. W. Sutton, L. A. Cervini, J. E. Rivier, and W. W. Vale Comparison of an Agonist, Urocortin, and an Antagonist, Astressin, as Radioligands for Characterization of Corticotropin-Releasing Factor Receptors J. Pharmacol. Exp. Ther., February 1, 1999; 288(2): 729 - 734. [Abstract] [Full Text]

				D. Stanislaus, J. A. Janovick, T. Ji, T. M. Wilkie, S. Offermanns, and P. M. Conn Gonadotropin and Gonadal Steroid Release in Response to a Gonadotropin-Releasing Hormone Agonist in Gq{alpha} and G11{alpha} Knockout Mice Endocrinology, June 1, 1998; 139(6): 2710 - 2717. [Abstract] [Full Text] [PDF]

				S. C. Sealfon, H. Weinstein, and R. P. Millar Molecular Mechanisms of Ligand Interaction with the Gonadotropin-Releasing Hormone Receptor Endocr. Rev., April 1, 1997; 18(2): 180 - 205. [Abstract] [Full Text]